Compared to breast and gastric cancer studies where HER2‐directed treatments have demonstrated significant improvement in OS, clinical trials evaluating trastuzumab plus chemotherapy have not shown notable clinical benefits in patients with HER2‐positive NSCLC [25, 26, 27, 28, 29, 30, 31]. This evidence concerns the gene ERBB2 and gastric cancer.